Skip to content

Trial Summary

The purpose of this phase III study is to determine whether regorafenib is effective in prolonging survival in patients with advanced gastro-oesophageal carcinoma.



ACTRN/NCT /ethics:


Scientific title:

A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Sponsor / Cooperative group:

The Australasian Gastro-Intestinal Trials Group (AGITG)

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2016-11-01
Anticipated End Date2021-12-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Phone08 8204 4830
Principal InvestigatorProfessor Chris Karapetis
Recruitment StatusRecruiting
HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting
HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2240
Principal InvestigatorDr Caroline Bampton
Recruitment StatusRecruiting